Study Details

Back to Search Results

A study of gilteritinib, venetoclax and azacitidine as a combined treatment for people newly diagnosed with acute myeloid leukemia

This trial is recruiting
The study is currently recruiting participants.

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT05520567

Astellas Study ID

The unique identification code given by the study sponsor.

2215-CL-0203

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Leukemia - AML

Phase

These clinical trials are usually the first time an experimental treatment is studied in a small group of people.

Phase 1

Age

18 Years - N/A

Sex

Female & Male

Product

gilteritinib

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Jan 2023 - Jul 2028

Masking

None (Open Label)

Enrollment number

70

A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients with Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) not Eligible for Intensive Induction Chemotherapy

Study summary

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A study of gilteritinib, venetoclax and azacitidine as a combined treatment for people newly diagnosed with acute myeloid leukemia? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Memorial Cancer Institute

Pembroke Pines, United States, 33028

Recruiting
Contact Us

Sarah Cannon Research Institute

Denver, United States, 80218

Recruiting
Contact Us

The University of Texas MD

Houston, United States, 77030

Recruiting
Contact Us

Novant Health

Winston-Salem, United States, 27103

Recruiting
Contact Us

City of Hope Nat'l Medical Center

Duarte, United States, 91010

Recruiting
Contact Us

Robert H. Lurie Comprehensive Cancer Center

Chicago, United States, 61612

Recruiting
Contact Us

University of Pennsylvania-Abramson CCC-Dept. of Hem Onc

Philedelphia, United States, 19104

Recruiting
Contact Us

University of Maryland

Baltimore, United States, 21201

Recruiting
Contact Us

Univ. of California – Irvine

Irvine, United States, 92697

Recruiting
Contact Us

Thomas Jefferson University Hospital

Philedelphia, United States, 19107

Recruiting
Contact Us

Motefiore-Einstein Center for Cancer Care

Bronx, United States, 10461

Recruiting
Contact Us

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo